Company intelligence / Profile preview
Aadi Bioscience, Inc.
- Ownership
- Public · AADI
- Employees
- ~40
- Development stage
- Other
Overview
Aadi Bioscience developed and commercialized FYARRO® (albumin-bound sirolimus), FDA-approved for advanced PEComa. In March–April 2025 the company rebranded to Whitehawk Therapeutics after pivoting away from its commercial business due to a failed Phase II trial in solid tumors. The company now focuses on preclinical development of three newly licensed antibody-drug conjugate programs targeting various cancers. The proceeds from selling its legacy business are expected to fund operations through at least the end of 2028.[4][7]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs) [current focus][7][8]Albumin-bound nanoparticle sirolimus ("nab-sirolimus") [legacy asset][4][6]
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Aadi Bioscience, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aadi Bioscience, Inc..